Tezepelumab as add‐on treatment for severe asthma

Steve Chaplin

Found an issue? Give us feedback

Prescriberarrow_drop_down

Prescriber

Article . 2023 . Peer-reviewed

License: Wiley Online Library User Agreement

Data sources: Crossref

Tezepelumab as add‐on treatment for severe asthma

descriptionPublicationkeyboard_double_arrow_right Article 01 Mar 2023 English Publisher:WileyJournal:Prescriber, volume 34, pages 13-14 (issn: 0959-6682, eissn: 1931-2253,

Copyright policy )

Authors: Steve Chaplin;

doi: 10.1002/psb.2050

Tezepelumab as add‐on treatment for severe asthma

- Summary
- Metrics

Abstract

Tezepelumab (Tezspire) is a new monoclonal antibody therapy for add‐on treatment in adolescents and adults with inadequately controlled severe asthma. This article outlines its mode of action, indication and clinical trial outcomes.

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	2
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average